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Abstract 
Viral infections contribute to approximately 12% of cancers worldwide, with the vast majority occurring in developing 
countries and areas. Two DNA viruses, Epstein‑Barr virus (EBV) and human papillomavirus (HPV), are associated with 
38% of all virus‑associated cancers. The probability of one patient infected with these two distinct types of viruses is 
increasing. Here, we summarize the co‑infection of EBV and HPV in human malignancies and address the possible 
mechanisms for the co‑infection of EBV and HPV during tumorigenesis.
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Introduction
Oncogenic viruses include various classes of DNA and 
RNA viruses that are necessary but not sufficient for the 
development of all types of malignancies. A unifying 
theme is that cancer develops in a minority of persistently 
infected people and only after many years of chronic 
infection [1]. The majority of these cancers result from 
infection with an oncovirus. Viral infections contribute to 
approximately 12% of cancers worldwide, the vast major-
ity (>85%) of which occurs in developing countries and 
areas [2, 3]. Epstein-Barr virus (EBV) and human papil-
lomavirus (HPV), which are DNA viruses, were reported 
to be linked with 38% of all virus-associated cancers [4]. 
EBV is an oncogenic gamma-1 herpesvirus that infects 
more than 90% of the adult population worldwide, and it 
has powerful transforming potential for B lymphocytes 
in  vitro, contributing to several lymphoid malignancies, 
including B, T, and natural killer (NK) cell lymphomas 
and epithelial carcinomas such as nasopharyngeal car-
cinoma (NPC) [4–9]. The viruses associated with the 
greatest number of cancer cases are HPVs, which cause 
cervical cancer and several other epithelial malignancies 
[10].
The probability of a single patient who is infected with 
two or more distinct types of viruses is increasing [11, 
12]. Viral infections within carcinoma cells are not mutu-
ally exclusive. In the last 20  years, substantial attention 
has been paid to the observation that human immuno-
deficiency virus (HIV)-infected patients have a high risk 
of developing some cancers such as cervical carcinoma 
and some non-Hodgkin lymphomas [12]. Notably, can-
cers arising in the context of HIV-induced immunosup-
pression are usually associated with subsequent infection 
by oncogenic viruses such as EBV and HPV [13]. How-
ever, the detailed mechanism of the cooperation remains 
largely unknown, and further studies are needed to 
address whether this cooperation plays a critical role in 
tumor development.
The implication that HPV has a role in the carcinogen-
esis and prognosis of cervical cancer is well established. 
However, many studies have found that HPV infection 
is linked to NPC as an etiologic factor [14–17] and that 
EBV is also present in cervical cancer [18, 19] and pros-
tate cancer [20]. The co-existence of both EBV and HPV 
has also been reported in other epithelial cancers, such 
as breast cancer [21]. The co-infection of EBV and HPV 
plays an important role in the initiation of a neoplastic 
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transformation of carcinogenesis [22]. Interestingly, 
there is an interaction between EBV and HPV (whole 
viruses) in  vivo as well as an interaction between HPV 
and EBV oncoproteins [e.g., latent membrane protein 
1 (LMP1) reduces apoptosis in  vitro] [23]. Whether the 
host is co-infected with two viruses, such as EBV and 
HPV, is unknown. Here, we discuss the co-infection of 
EBV and HPV in human malignancies and possible com-
mon characterizations in the molecular mechanisms of 
tumorigenesis.
Co‑infection of EBV and HPV in NPC
NPC is a common tumor in South China and Southeast 
Asia, but it is a rare disease among Caucasians [24, 25]. 
For many decades, the major etiologic factors proposed 
for NPC pathogenesis have included genetic susceptibil-
ity, environmental factors, and EBV infection [26]. How-
ever, although EBV infection is regarded as the primary 
factor for NPC, NPC patients are occasionally EBV-neg-
ative [27, 28]. Over the last decade, several studies have 
reported that HPV also exists in some EBV-negative NPC 
patients [14–17, 29]. HPV is considered one of the co-
factors because it can transform epithelial cells, and the 
HPV DNA level is high in NPC biopsies.
The co-infection of EBV and HPV is usually found in 
NPC patients from endemic regions. In one study, NPCs 
in Iranian patients were detected by in situ hybridization, 
and a low percentage (15%) of EBV-positive NPC patients 
had HPV sequences (HPV type 6/11 or HPV type 16/18) 
[30]. Approximately 34% of NPC patients from Morocco 
had co-infection of HPV and EBV [31]. The co-infection 
of EBV and HPV was found in 47.7% of 88 Chinese NPC 
patients, and the “high-risk” types, including HPV types 
16 and 18, accounted for 66.7% of 45 HPV-positive sam-
ples [32]; EBV was associated with types 2 and 3 NPC 
[the World Health Organization (WHO) classification] 
[33], which are non-keratinizing-type NPC, indicating 
that EBV infection might facilitate HPV infection.
However, co-infection of EBV and HPV is less common 
in NPC patients from some regions in the United States 
compared with that from the South China. HPV might 
be the etiologic factor in some EBV-negative, non-kerati-
nizing NPC patients, including Caucasian North Ameri-
can patients [17]. A recent study in a population with a 
low incidence of NPC reported that both HPV-positive 
and EBV-positive NPC patients had similar overall sur-
vival (OS), whereas the HPV-positive, EBV-negative NPC 
group had shorter OS [28], which supported the etio-
logic role of HPV in NPC. Dogan et al. [28] reported that 
HPV and EBV infections were mutually exclusive in a 
low NPC incidence population; however, HPV positivity 
was significantly associated with WHO grade 2 tumors 
[34]. Numerous clinical studies reported that HPV type 
18 infection was detected in NPC tumor tissues (mainly 
WHO type II) [14, 16, 17, 30, 31, 35, 36]; moreover, HPV 
types 16, 31, 35, 45, and 48 were detected in Moroccan 
patients with NPC type III [31]. As a result, HPV infec-
tion may act alone and have an etiologic role in the devel-
opment of non-endemic, EBV-negative NPC, which is 
consistent with the results of the study of Caucasian 
North American patients with NPC [27] and another 
study of a United Kingdom population [37]. Both stud-
ies also indicated that EBV-negative NPC were associ-
ated with worse outcomes independent of HPV infection 
compared with EBV-positive NPC. Additionally, EBV-
negative NPC in Caucasian patients was associated with 
smoking and the presence of HPV [38]. In contrast, EBV-
negative NPC was not associated with HPV infection in 
Chinese patients [38, 39].
Using established EBV-negative NPC cell lines and 
advanced molecular biology techniques, our understand-
ing of molecular alternations in these cells has been tre-
mendously improved [40–43]. Until recently, only a few 
NPC cell lines, such as C666-1, that stably harbor the 
EBV genome have been used as EBV-positive models 
[44]. Other cell lines, such as CNE2, 5-8F, and 6-10B, 
may be EBV-positive in early cell culture passages, but 
the EBV genome was lost after subsequent passages. In 
these cells, it was determined that a single HeLa-related 
somatic cell hybrid was misidentified as an EBV-negative 
NPC cell line because the short tandem repeat profiles in 
NPC cell lines were not completely matched with that in 
HeLa cells [45]. Moreover, RNA sequencing showed that 
for HPV type 18-positive cervical adenocarcinoma cells, 
HeLa cells were a likely source of contamination in NPC 
cells CNE1 and HONE1 [46]. A new breakpoint and inte-
gration pattern has been observed and is being used to 
differentiate cells. It is also possible that these NPC cell 
lines derived from patients might have naturally acquired 
HPV infection prior to the establishment [16]. In con-
trast, low p53 expression was reportedly in HeLa cells, 
whereas CNE1 and HNE2 NPC cells had a high level of 
p53 expression [42, 47, 48]. Interestingly, these cells were 
not NPC type II, in which HPV type 18 is always detected 
[31]. HPV integrates into the host genome of HeLa cells 
[49] and cervical cancer tissues [50]; because EBV and 
HPV infections are mutually exclusive, it is easy to under-
stand how the EBV genome could be lost during passag-
ing these cells while HPV type 18 could still be detected. 
Moreover, HPV type 18 infection was not detected in 
other EBV-positive cells, such as AGS-EBV [51] and 
Akata-EBV [52], indicating that these cell lines might be 
used as good cell models for EBV-related research.
Co-infection of EBV and HPV is frequently found in 
endemic NPC, but it is less common in Caucasians than 
in Asian populations; HPV is an important etiologic 
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factor in EBV-positive NPC among Caucasians [15]. Fur-
thermore, co-infection of HPV and EBV may also coop-
eratively affect neoplastic transformation [53]. However, 
although HPV plays an etiologic role in EBV-negative 
NPC in Caucasians, more evidence is needed to confirm 
the roles of HPV in EBV-positive NPC in non-endemic 
regions. Moreover, several questions require further elu-
cidation. First, there is a high risk of co-infection of EBV 
and HPV in some regions, such as South China, but the 
ratio of co-infection of EBV and HPV in NPC patients 
remains unclear. Next, it is also unclear which virus, 
either EBV or HPV, contributes to the first infection in 
co-infected patients. It will be interesting to address the 
difference in pathological and epidemiological charac-
teristics among these NPC patients. Finally, the possi-
ble association of the HPV subtype and etiology in NPC 
requires further investigation. Of note, although genetic 
susceptibility of NPC in Asian ethnic groups has been 
well addressed [54–56], the association between genetic 
susceptibility factors and co-infection of HPV and EBV 
remains obscure.
Co‑existence of EBV and HPV in cervical cancer
Cervical cancer is the third most common malignancy 
in women and the fourth most common cause of death 
from cancer [57]. It is well known that there is a strong 
association between high-risk HPVs and cervical cancer 
[58]. Because it takes a long time for patients from being 
infected by HPV to developing cervical cancer, HPV is 
found in nearly 100% of cervical carcinoma cases; how-
ever, most women infected do not develop the disease, 
suggesting that other etiologies may be involved in the 
carcinogenesis of cervical neoplasm.
Many studies have found that there is a co-infection of 
high-risk HPV and EBV in cervical tissues [39, 59, 60], 
whereas some early reports did not report this finding 
[61, 62]. It would be of clinical significance to confirm 
whether EBV plays a causal role in cervical cancer devel-
opment or if it is merely a bystander in the process.
EBV can transform cells bearing the EBV/C3d (third 
component of complement, C3) receptor, making them 
receptive to other oncogenic stimuli [63, 64]. These 
receptors are widely expressed on ecto- and endo-cervi-
cal biopsies of the uterine cervix [65]. This indicates that 
EBV can be a “helper” in the development of cervical can-
cer. Unexpectedly, EBV can be sexually transmitted [66] 
and can replicate in cervical cells [67]. Similarly, chronic 
cervicitis may also facilitate the EBV infection [68]. 
Women with cervical intraepithelial neoplasia 1 (CIN1) 
or greater are almost four times likely to be EBV-positive 
than women without the disease [68]. EBV prevalence 
is associated with older age and a diagnosis of CIN1 or 
greater. In cervical carcinoma, the co-infection rate was 
the highest (67%) in squamous cell carcinoma, whereas 
it was the lowest (7%) in normal cervical tissue [59]. The 
remarkable difference in EBV infection noted between 
normal cervixes and squamous cell carcinoma suggests 
that the co-infection of the two viruses in the cervix may 
facilitate cervical cancer progression and act as a marker 
of poor prognosis in patients with cervical cancer.
HPV types 16 and 18 are the two most common high-
risk HPV types and were involved in the development of 
cervical cancer [69, 70]. HPV type 58 is relatively prev-
alent in China and other Asian countries, and genome-
wide analysis confirmed its expression in cervical lesions 
[71–74]. The infection of both high-risk HPV types 
(such as HPV type 58) and EBV display considerable 
geographic variation, and, prior to performing epide-
miologic studies, it is necessary to determine which HPV 
type might co-infect with EBV. Moreover, the clinical rel-
evance of genital infection caused by EBV may be due to 
the virus’s capability for cellular transformation, which 
possibly contributes, as a co-factor, to the development 
of malignancy.
EBV and HPV in breast cancer
Breast cancer is the second leading cause of cancer-
related death in women around the world [75]. The eti-
ology of human breast cancer is significantly affected by 
multiple risk factors (age, hormones, alcohol use, diet, 
familial history, etc.). As viruses are etiologic agents of 
some human cancers, researchers have become inter-
ested in identifying viral agents for breast cancer.
Interest in EBV as a possible breast agent arose from 
the presence of EBV in breast tissue [76]. Some research-
ers have also proposed that HPV is a candidate virus in 
breast cancer after finding that oncogenic HPV could 
immortalize human mammary epithelial cells [77]. Inter-
estingly, HPV-16 E6/E7, the genotype that is most fre-
quently detected in cervical uterine cancer, was the only 
genotype identified in HPV-positive breast cancer and 
integrated into the host genome in all cases. No HPV 
DNA sequences were found in invasive breast carcinoma 
[78, 79]. However, high-risk HPV types 16, 18, and 33 
have been identified in breast cancers from widely differ-
ent populations [80]. Clearly, HPV and EBV prevalence 
in mammary epithelial cells from breast cancer patients 
is relatively low; therefore, determining the direct etio-
logic role of these viruses is excluded.
EBV is a major contributor to Hodgkin lymphoma, and 
significant associations exist between the incidence of 
Hodgkin lymphoma and breast cancer, suggesting that 
EBV may act as an etiologic factor for some breast can-
cers [81]. Some EBV-positive cancer cells have the same 
histological characteristics as Reed-Sternberg cells, sug-
gesting that EBV-positive lymphocytes infiltrate breast 
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tissues and transmit EBV to breast epithelial cells [21]. 
Women with HPV-positive breast cancer at the age of 
diagnosis are younger than those with HPV-negative 
breast cancer [21], supporting the hypothesis that women 
with HPV-positive breast cancer may have sexually trans-
mitted HPV [82].
Co-infection of EBV and HPV appears to be present in 
a significantly higher proportion in breast cancers than in 
normal breast epithelial cells [21, 83]. The Glenn group 
reported that HPV and EBV co-exist in several human 
cancers, and the presence of these viruses in breast can-
cer is associated with young age at diagnosis and, possi-
bly, an increased breast cancer grade [21].
As many studies provide insufficient evidence, testing 
in larger sample groups is needed to demonstrate that 
EBV and HPV are associated with breast cancer [84]. To 
clarify whether the co-infection of EBV and HPV pro-
motes the development of breast cancer, further studies 
are needed.
EBV and HPV in prostate cancer and other 
malignancies
Among men, prostate cancer is the most common can-
cer and the second leading cause of cancer-related death 
[85]. Because HPV is always detected in both benign and 
malignant prostate tissues, it is considered an important 
risk factor for prostate cancer [86].
Although EBV is a ubiquitous virus with known onco-
genic potential, few investigations have demonstrated its 
association with prostate cancer. Several reports showed 
that EBV was present in prostate tissues. In Sweden, EBV 
was present in 8.8% (31 of 352) of benign and malig-
nant prostate tissues [87], and in the United States, EBV 
was present in 8% (16 of 200) of all normal, benign, and 
malignant prostate tissues [88]. In another study, approx-
imately 37% (7 of 19) of prostate cancer patients had EBV 
infection [89].
Both HPV type 18 and EBV gene (EBNA1) sequences 
were identified in a high and approximately equal pro-
portion of normal, benign, and prostate cancer speci-
mens [20]. The sequences were located in the nuclei of 
prostate epithelial cells. These observations are consist-
ent with those in studies of high-risk HPVs [86] and stud-
ies of EBV in prostate cancer [20, 88, 89]. The frequency 
of co-infection of EBV and HPV was significantly higher 
in prostate cancer (55%) than in benign (15%) and normal 
prostate (30%) specimens. Additionally, experimental 
evidence shows that HPV and EBV work together to pro-
mote the proliferation of cultured cervical cells [23], sug-
gesting the same may be true for prostate epithelial cells.
We summarized the ratio of co-infection of EBV and 
HPV in several malignancies (Table 1). It is possible that 
HPV exerts its oncogenic influences in concert with co-
factors, including a possible collaboration with EBV. 
Although the prostate is a niche for multiple viral and 
other infections, some of which have oncogenic poten-
tial, few investigations have focused on the relationship 
between prostate cancer and viral infection. Increasing 
data are needed to clarify the role that the co-infection 
of HPV and EBV plays in the carcinogenesis of prostate 
cancer.
Lung cancer is the leading cause of cancer-related 
death in the world, and it is unlikely that HPV or EBV are 
important etiologic agents in lung adenocarcinoma, even 
among people who have never smoked [90]; in fact, in 
one study, only 1 of 219 patients with lung squamous cell 
carcinoma tumors was positive for HPV 16 [91]. Gastric 
carcinoma is the second leading cause of cancer-related 
death in developed and developing countries, and it has 
a widely varying geographic incidence [92]. In one study, 
RNA sequencing demonstrated that only 5.6% of gastric 
carcinoma cases harbored EBV-encoded transcripts, and 
none of the tumors showed evidence of EBV integration 
into the host genome [91]. Another report indicated that 
Table 1 Summary of co‑infection of EBV and HPV in several malignancies
EBV Epstein-Barr virus; HPV human papillomavirus; NPC nasopharyngeal carcinoma; EBER EBV-encoded RNA; BALF1 BamH1 A fragment leftward reading frame 1; BARF-
1 BamH1-A right frame 1; LMP1 latent membrane protein 1; EBNA3B EBV nuclear antigen 3B; EBNA-1 EBV nuclear antigen
Tumor type Co-infection Subtype of HPV EBV product(s) Reference
NPC 15% (Iran) 6/11, 16/18 EBER [30]
34% (Morocco) 16, 31, 45, 48 EBER [31]
42% (China) 18 EBER [32]
Cervical cancer 31.8% 16, 18, 58 EBER [39]
12.5%–69% 16, 18 BALF1, BARF‑1, LMP1 [59]
21.2%–64.3% 16, 18 EBNA3B [60]
Breast cancer 35% 16, 18, 33 LMP1, EBNA‑1 [21]
Prostate cancer 8.8% (Sweden) 18 EBER [88]
37% (United States) 18 EBER, EBNA‑1 [89]
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EBV integration was found in approximately 9% of malig-
nant epithelial cells in gastric carcinoma [93].
Esophageal squamous cell carcinoma (ESCC) is preva-
lent worldwide and is particularly common in certain 
regions in Asia, including Southeast China. One group 
of researchers showed that EBV infection contributed to 
the molecular pathogenesis of ESCC [94], whereas other 
groups indicated that EBV was not associated with ESCC 
[95, 96]. On the basis of the causal relationship between 
HPV infection and the carcinogenesis of ESCC, serologi-
cal evidence from a high-incidence area of China further 
supports that ESCC is infected with HPV type 16 [97–
99]; however, this finding contradicted that of another 
group [100]. Clearly, the prevalence of co-infection of 
EBV and HPV in ESCC requires further study.
Altogether, it is unclear whether the co-existence of 
EBV and HPV acts as a promoter or bystander in the 
development of these carcinomas aforementioned. To 
improve the treatment and prognosis, it is important, 
from the standpoint of genetic etiology, to clarify the 
connection.
APOBEC3 deaminases may promote co‑infection 
of EBV and HPV
Oncogenic viruses induce cancer by a variety of mecha-
nisms that do not include the viral episome or lytic 
replication; for example, the immune system can have 
a deleterious or protective role, with increasing immu-
nosuppression in human virus-associated cancers 
and with activating DNA damage response [4, 101]. 
Recently, a family of proteins that includes the apo lipo-
protein B mRNA editing enzyme catalytic polypeptide 
3 (APOBEC3) was well characterized due to the ability 
to provide innate immunity from a variety of exogenous 
pathogens, including viral infection [102, 103]. Cytidine 
deaminases of the APOBEC3 family all have specificity 
for single-stranded DNA, which may become exposed 
during replication or transcription of double-stranded 
DNA. Three human APOBEC3A (hA3A), hA3B, and 
hA3H genes are expressed in keratinocytes and the skin; 
all of them induce hypermutation in HPV16 DNA upon 
beta interferon stimulation in benign and precancerous 
lesions during natural viral infection [104–106]. Interest-
ingly, APOBEC3 is capable of editing both EBV and HPV 
by inducing cytidine-to-uracil mutations in viral DNA 
[107]. In one study of early-stage breast carcinogenesis, 
HPV type 18 infection induced APOBEC3B activity, lead-
ing to genome instability [108], whereas in another study 
APOBEC3 induced E2 hypermutation in HPV16 DNA 
upon beta interferon stimulation in cervical keratinocytes 
[105]. In HPV-induced tumorigenesis, APOBEC3 also 
mutated other host genomic regions, including those of 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic 
subunit alpha (PIK3CA) helical domain [109]. Interest-
ingly, EBV-positive gastric cancer displayed recurrent 
PIK3CA mutations [110]. It is possible that APOBEC3 
increases the chance of viral DNA integration in the host 
by inducing mutations and genome instability after viral 
infection.
Perspectives and conclusions
Studies on the roles of chromatin in the regulation of 
viral infections have revealed the significance of dynamic 
viral-host chromatin interactions in determining viral 
infections as well as the interplay between viral-encoded 
proteins in modulating chromatin. These interactions 
are especially significant for multiple epigenetic events, 
such as chromatin assembly, histone and DNA modifi-
cations, and higher-order chromosome structures that 
control viral episome generation and maintenance after 
viral infection [111–113]. Two scenarios of coopera-
tion between EBV and HPV after co-infection in cancer 
development should be further addressed; the detailed 
epigenetic mechanism of this cooperation remains largely 
unknown, and further studies are necessary to elucidate 
whether co-infection of EBV and HPV plays any role in 
the development of malignant tumors. Moreover, chro-
matin control of viral co-infection also represents a new 
field with potential targets for the development of novel 
antiviral therapies. Of note, most arguments of co-infec-
tion are mainly supported only by polymerase chain reac-
tion data and in situ hybridization; additional evidence of 
co-infection of both EBV and HPV or gene products to 
the same cells or tissues should be addressed.
The effect of such reprogramming on the viral life cycle 
also remains unknown; it will be interesting to evaluate 
the host-virus interactions through combined genome-
wide analyses. Recently, a large-scale functional genomic 
analysis of EBV, together with over 700 publicly available 
high-throughput sequencing data sets for human lymph-
oblastoid cell lines, were mapped to the EBV genome, 
and viral lytic genes were found co-expressed with cel-
lular cancer-associated pathways, indicating that the 
lytic cycle may play an unexpected role in virus-medi-
ated oncogenesis [114, 115]. Moreover, a comprehensive 
resource describing a systematic quantitative analysis of 
temporal changes in the host and viral proteins through-
out the course of a productive infection could provide 
dynamic views into virus-host interactions [116]. Further 
studies on genome-wide approaches will lead to more 
comprehensive models of viral persistence and its role in 
the interplay between co-infection of EBV and HPV and 
the infected cells.
Oncogenic virus-induced cancers are an important 
global concern. Remarkable progress continues to be 
made in the global fight against cancer by preventing the 
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spread of these viruses, by developing and distributing 
safe and effective vaccines against them, and by identi-
fying the oncogenic mechanisms used by these viruses, 
enabling the development of new treatment options for 
these virally associated human malignancies. Although 
there is a vaccine for HPV [117], there is not one for 
EBV (50 years after EBV was identified). Now, two pre-
ventive vaccines for HPV types 16/18 and HPV types 
6/11/16/18 are commercially available in more than 140 
countries and regions, and the implementation rate of 
these two HPV vaccines has reached approximately 80% 
among suitable women in Australia. Interestingly, DZ1 is 
regarded as a phosphorothioate-modified “10–23,” DNA-
zymes were specifically targeted to the LMP1 mRNA, 
and DZ1 treatment increases the radiosensitivity of NPC 
to standard radiotherapy [118–125]. The DZ1 treatment 
is safe and has been shown to be efficacious in differ-
ent modes, indicating the potential for DZ1 therapeutic 
approaches for the treatment of EBV-related cancers.
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